Insmed (INSM) Total Non-Current Liabilities (2010 - 2026)
Insmed (INSM) posted quarterly Total Non-Current Liabilities of $1.4 billion for Q1 2026, down 9.96% year-over-year from $1.5 billion in Q1 2025, and down 10.17% quarter-over-quarter from $1.5 billion in Q4 2025.
Insmed (INSM) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Insmed's Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $1.4 billion for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 9.96% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at $1.4 billion (down 9.96% YoY), while the FY2025 annual figure was $1.5 billion, down 3.25% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $1.4 billion, down from $1.5 billion in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $1.6 billion in Q2 2024, with the low at $953.5 million in Q2 2022.
- The 5-year median for Total Non-Current Liabilities is $1.5 billion (2025), against an average of $1.4 billion.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities surged 100.91% in 2022, then tumbled 34.46% in 2025.
- Insmed's Total Non-Current Liabilities stood at $1.5 billion in 2022, then increased by 4.42% to $1.6 billion in 2023, then dropped by 0.39% to $1.6 billion in 2024, then dropped by 3.25% to $1.5 billion in 2025, then slipped by 10.17% to $1.4 billion in 2026.
- Business Quant data shows INSM's Total Non-Current Liabilities at $1.4 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 378.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.17 Bn |
| Mar 31, 2026 | 1.37 Bn |
| Dec 31, 2025 | 1.52 Bn |
| Sep 30, 2025 | 1.41 Bn |
| Jun 30, 2025 | 1.05 Bn |
| Mar 31, 2025 | 1.52 Bn |
| Dec 31, 2024 | 1.57 Bn |
| Sep 30, 2024 | 1.57 Bn |
| Jun 30, 2024 | 1.60 Bn |
| Mar 31, 2024 | 1.55 Bn |
| Dec 31, 2023 | 1.58 Bn |
| Sep 30, 2023 | 1.54 Bn |
| Jun 30, 2023 | 1.59 Bn |
| Mar 31, 2023 | 1.56 Bn |
| Dec 31, 2022 | 1.51 Bn |
| Sep 30, 2022 | 1.02 Bn |
| Jun 30, 2022 | 953.51 Mn |
| Mar 31, 2022 | 967.32 Mn |
| Dec 31, 2021 | 757.37 Mn |
| Sep 30, 2021 | 783.05 Mn |